Menu

Speaking of Cancer Research

A selection of notable quotes from the annual American Association for Cancer Research meeting

Apr 20, 2016
Tanya Lewis, Jef Akst, Mary Beth Aberlin

JEF AKST

This week in New Orleans, Louisiana, tens of thousands of scientists gathered to discuss the latest and greatest in the world of cancer research. Hot topics included cancer metabolism, neoantigens (antigens specific to tumor cells), epigenetic regulators of cancer, microRNAs, and more.

We are on the cusp of a real inflection point in the fight against cancer.

—US Vice President Joe Biden, in his remarks at AACR’s final plenary session “Highlights 2016: Vision for the Future”

I fear that I am a member of an endangered species at a time when the whole ethic of doing discovery-oriented research is being marginalized. . . . I hope that one day this trend will reverse itself.

Robert Weinberg, MIT, on receiving the 13th annual AACR Award for Lifetime Achievement in Cancer Research

I expect over the next decades we will see a very large expansion of the use of microRNAs to treat cancer. . . . It could be as large as monoclonal antibodies.

Phillip Sharp, MIT, in his opening comments at an AACR symposium on the roles of noncoding RNAs in cancer

The main message is that cancer immune-oncology is living up to its promise. Steady increase in durable remissions reported by a variety of groups. The main clinical challenge is how to efficiently conduct combination trials with other targeted agents, since preclinical models are pretty useless in predicting.

Carl June, University of Pennsylvania Perelman School of Medicine, in his talk at an AACR session on CAR T-cell therapy

So this suggests, contrary to what’s in every textbook, that our cells are capable of using extracellular proteins as a meaningful source of nutrients.

Craig Thompson, Memorial Sloan Kettering Cancer Center, during his plenary talk on cancer metabolism

The current understanding of what causes cancer focuses on the function of individual genes. . . . What’s missing in this picture is any discussion of aneuploidy.

Stephen Elledge, Harvard Medical School, in his AACR talk on aneuploidy and cancer

Data has been no more democratic than it is now. Take advantage of it to propel your own science.

Nancy Davidson, University of Pittsburgh Medical Center and incoming AACR president, in her talk on advice to young scientists

This is personal for us. . . . Our son Beau, my mother, my father. But it’s also bigger than us. It affects millions of people around the world, every day.

—US Second Lady Jill Biden in her remarks at AACR’s final plenary session “Highlights 2016: Vision for the Future”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.